Curis (NASDAQ: CRIS) — Perfil da empresa, notícias e dados financeiros
Curis develops innovative cancer treatments aimed at improving patient outcomes through advanced drug therapies.
Curis
Curis (NASDAQ:CRIS) focuses on innovating and developing new treatments in the fight against cancer. With a passion for leveraging the latest in molecular and cancer biology to unlock new therapeutic pathways, Curis is dedicated to the discovery and development of groundbreaking drug candidates. The company's projects span various stages of clinical trials, aiming to address some of the most challenging oncological targets. Central to their mission is the objective to provide novel, effective therapies to improve the lives of patients struggling with cancer. By pushing the boundaries of current treatment paradigms, Curis endeavors to make significant contributions to oncology and patient care.
Resumo
Operações
Produtos e/ou serviços de Curis
- CA-170, a first-in-class oral small molecule targeting PDL1 and VISTA for advanced solid tumors and lymphomas.
- CA-4948, an IRAK4 inhibitor aimed at treating patients with non-Hodgkin lymphoma.
- Fimepinostat, a dual inhibitor of PI3K and HDAC for the treatment of patients with lymphomas.
- CA-327, a first-in-class oral small molecule targeting PDL1 and TIM3 for advanced solid tumors and lymphomas.
- Collaboration with Aurigene in the discovery and development of small molecule therapeutics in oncology.
equipe executiva do Curis
- James E. DentzerPresident, CEO, Secretary, Treasurer & Director
- Diantha DuvallCFO and Principal Financial & Accounting Officer
- Jonathan B. ZungChief Development Officer
- Mark W. NoelVice President of Technology Management & Intellectual Property
- Rachel BlasbalgSenior Director of Human Resources
- Ahmed M. HamdyChief Medical Officer
Últimas notícias sobre a Curis
Principais indicadores financeiros
Resultados divulgados pela Curis, em USD.
- Cap. de mercado
- 1,1 mi
- Receita (TTM)
- 4,3 mi
- P/L
- 0.3
- LPA (diluído, TTM)
- 1.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 9,4 mi | -32,9 mi | -7,6 mi | |
| 10,9 mi | -44,5 mi | -43,4 mi | |
| 10 mi | -48,3 mi | -47,4 mi | |
| 10,2 mi | -53 mi | -60,3 mi |